Novo Nordisk cut its 2025 guidance and outgoing CEO blames the compounding market for it.
Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook
July 29, 2025
You may also like
Indices by TradingView
What To Expect From Amazon’s (AMZN) Q2 Earnings
July 29, 2025
AMD Shares Climb as Ryzen Threadripper?9000 Set to Debut
July 29, 2025
Categories
Indices by TradingView
Add Comment